Key Highlights
- 6:00 a.m. ET on October 21, 2026 is when Elevance Health (NYSE:ELV) releases third quarter results, with a call at 8:30 a.m. ET. The company guided 2026 adjusted EPS to at least USD 27.00 and GAAP EPS to at least USD 20.10, both raised in July.
- 10.9 percent is the gain in Elevance Health (NYSE:ELV) from USD 386.43 on October 2 to USD 428.43 on October 15, simple arithmetic on two published closes. The quote sits about 1.8 percent below the 52-week high of USD 436.24.
- 89.7 percent was the second quarter benefit expense ratio, up 80 basis points, on elevated medical cost trend in Government businesses. Adjusted EPS of USD 7.45 fell from USD 8.84 and included about USD 0.80 a share of below-the-line benefit for Elevance Health (NYSE:ELV).
- USD 49.8 billion of operating revenue, up 0.8 percent, came with medical membership of about 44.9 million, down 1.5 percent. Medicaid fell 4.3 percent to 8.36 million members and ACA individual fell 2.3 percent to 1.32 million, which the company called anticipated attrition.
Setting the Bar for October 21
Elevance Health (NYSE:ELV) raised its 2026 adjusted EPS floor to at least USD 27.00 on July 15, 2026, and gave no third quarter guidance. A year earlier, third quarter adjusted EPS was reported at USD 6.03 against a consensus of USD 4.94. The stock gained about 10.9 percent in two weeks without a company announcement beyond its 2027 Medicare Advantage plans, so the move looks sector driven, coinciding with Humana's improved Star Ratings on October 9 and 10.
Cost Trend and Membership Mechanics
A benefit expense ratio is the share of premiums paid out for medical care, so a rise of 80 basis points to 89.7 percent directly squeezes profit. The company blamed Government businesses, partly offset by better ACA results. Membership attrition cuts revenue but can improve margins when exiting members were unprofitable. Days in claims payable were 45.4, up 2.9 days, a measure of claims reserves. The company repurchased 0.7 million shares for USD 234 million in the second quarter, with about USD 5.3 billion of authorization left.
Analyst Views and Risks
Barclays raised its target to USD 469 from USD 457 on about October 8, and Guggenheim to USD 460 from USD 455 on about October 13, both above the USD 428.43 quote. BofA lifted its target to USD 480 from USD 460 in September. Risks include a cost trend surprise in Medicaid or Medicare, a lower ACA risk pool, and a market value of USD 92.91 billion that already prices some recovery after a 52-week low of USD 274.84.
Where Things Stand
It depends. Elevance Health (NYSE:ELV) can extend the 10.9 percent rally only if the October 21, 2026 report shows the benefit expense ratio holding near 89.7 percent and the USD 27.00 floor staying intact, because the run looked sector driven and the stock is already about 1.8 percent below its high. Evidence is balanced: raised guidance and rising targets support the case, while falling membership and a USD 7.45 second quarter EPS against USD 8.84 a year ago keep earnings quality in question. Next catalysts are the 6:00 a.m. ET release and the 8:30 a.m. ET call.






Please wait processing your request...